Precision BioSciences (NASDAQ:DTIL) CFO Sells $31,292.16 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CFO John Alexander Kelly sold 8,149 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $3.84, for a total transaction of $31,292.16. Following the completion of the sale, the chief financial officer owned 125,883 shares in the company, valued at $483,390.72. This represents a 6.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

John Alexander Kelly also recently made the following trade(s):

• On Wednesday, January 21st, John Alexander Kelly sold 15,213 shares of Precision BioSciences stock. The stock was sold at an average price of $4.03, for a total transaction of $61,308.39.

Precision BioSciences Trading Down 3.3%

NASDAQ:DTIL opened at $3.79 on Friday. The stock has a market capitalization of $86.79 million, a price-to-earnings ratio of -0.45 and a beta of 1.31. Precision BioSciences, Inc. has a 52 week low of $3.53 and a 52 week high of $8.82. The company has a quick ratio of 3.45, a current ratio of 3.45 and a debt-to-equity ratio of 1.35. The firm has a 50 day moving average of $4.11 and a 200 day moving average of $5.00.

Hedge Funds Weigh In On Precision BioSciences

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its stake in Precision BioSciences by 5.5% during the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after purchasing an additional 4,025 shares during the last quarter. Bridgeway Capital Management LLC purchased a new position in Precision BioSciences during the 2nd quarter worth approximately $260,000. Corient Private Wealth LLC acquired a new stake in Precision BioSciences during the 2nd quarter valued at approximately $425,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Precision BioSciences during the 3rd quarter valued at approximately $72,000. Finally, Vanguard Group Inc. increased its stake in shares of Precision BioSciences by 21.5% in the third quarter. Vanguard Group Inc. now owns 492,596 shares of the company’s stock worth $2,719,000 after acquiring an additional 87,242 shares during the period. 37.99% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Precision BioSciences in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $60.00.

Precision BioSciences Company Profile

Precision BioSciences is a clinical?stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno?oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin?out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.